Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Syros Pharmaceuticals
< Previous
1
2
Next >
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
May 03, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
March 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Participate in Upcoming Investor Conferences in March
February 28, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
February 23, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Announces Clinical Updates and 2023 Strategic Priorities
January 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 23, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
December 12, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
December 10, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
December 05, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 14, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 07, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
November 03, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 09, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
August 03, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
August 02, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
July 05, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
TYME
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Present at JMP Securities Life Sciences Conference
June 08, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 16, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
May 09, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 29, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Tickers
SYRS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.